Berlin, Germany

Martin Krüger

USPTO Granted Patents = 6 

 

Average Co-Inventor Count = 9.4

ph-index = 4

Forward Citations = 101(Granted Patents)


Company Filing History:


Years Active: 2005-2017

Loading Chart...
Loading Chart...
6 patents (USPTO):

Sure, here is the article about inventor Martin Krüger:

Title: Unveiling the Ingenious Inventor: Martin Krüger

Introduction:

Martin Krüger, a distinguished inventor, hails from the vibrant city of Berlin, Germany. With a keen eye for innovation and a mind brimming with creativity, he has made significant contributions to the field of pharmaceutical inventions. Let's delve into the world of this accomplished inventor and explore his remarkable journey.

Latest Patents:

Martin Krüger has recently patented two groundbreaking discoveries:

1. BET protein-inhibiting 5-aryltriazoleazepines: A novel class of compounds designed to inhibit BET proteins, specifically BRD4, for the treatment of hyperproliferative disorders, including neoplastic disorders. These compounds show promise in various medical conditions such as viral infections, neurodegenerative disorders, inflammatory diseases, atherosclerotic disorders, and male fertility control.

2. Sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors: Pyrimidine derivatives acting as inhibitors of cyclin-dependent kinases and VEGF-receptor tyrosine kinases. These compounds hold potential in the treatment of diverse diseases, showcasing Martin Krüger's versatility and expertise in the pharmaceutical industry.

Career Highlights:

Throughout his career, Martin Krüger has worked with prestigious companies such as Schering Aktiengesellschaft and Novartis AG, where his innovative spirit and dedication have shone brightly. His professional journey is adorned with numerous accomplishments and a relentless pursuit of excellence in the realm of inventing pharmaceutical solutions.

Collaborations:

Martin Krüger's collaborative efforts have been instrumental in his success. Working alongside talented individuals like Andreas Huth and Dieter Seidelmann, he has fostered a culture of innovation and knowledge-sharing. These collaborations have led to synergistic outcomes and bolstered the impact of his inventions in the pharmaceutical landscape.

Conclusion:

In conclusion, Martin Krüger stands as a beacon of innovation in the field of pharmaceutical inventions. His relentless pursuit of novel solutions to complex medical challenges has not only enhanced his professional standing but also positively impacted the lives of many. With a rich tapestry of patents and a legacy of collaboration, Martin Krüger continues to inspire budding inventors and shape the future of pharmaceutical advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…